Recent Patents on Anti-Cancer Drug Discovery - Volume 18, Issue 2, 2023

The use of antibody-drug conjugates is expected to transform the management of human malignancy. Antibody-drug conjugates for cancer treatment are designed to deliver anticancer drugs to tumor cells. The main components of such conjugates are a monoclonal antibody that binds to a tumor antigen, an anticancer drug to inhibit tumor cell growth and a linker that serves to conjugate the antibody and drug. The anti Read More

Background: Lung cancer is one of the major killers among different kinds of cancer. Being a silent developer, the earliest detection and treatment of lung cancer is a challenging task. The existing therapeutic agents have lower efficacy. Nanotechnology can overcome the challenges posed by conventional approaches to ensure reliable diagnosis and treatment. Objectives: Various patents on nano diagnosis and nano delivery as Read More

Background: Cancer is the biggest killer that threatens human health. Poor bioavailability and strong drug resistance of cancer drugs are common defects. In recent years, drug delivery therapy based on nanotechnology has become a focused research area, and nano drug delivery system has been widely studied in cancer treatment. Objectives: Based on the articles and patents published on the application of nano drug deliver Read More

Recent developments in several areas are rekindling interest and empowering progress in improving therapeutic cancer vaccines. These advances have been made in target selection, vaccine technology, and approaches for reversing the immunosuppressive mechanisms exploited by cancers. Studies on diverse tumor antigens have revealed target properties, including high cell specificity and adequate immunogenicity, to affec Read More

Identifying cancer genomes has provided acuity into somatically altered genes athwart tumors, transformed our understanding of biology, and helped us design therapeutic strategies. Though the action of most cancer cells remains furtive yet many features of cancer surpass their genomes. Consequently, the characterization of tumor genome does not affect the treatment of many patients. Strategies to know the Read More

Background: The high heterogeneity of ovarian cancer (OC) brings great difficulties to its early diagnosis and prognostic forecast. There is an urgent need to establish a prognostic model of OC based on clinicopathological features and genomics. Methods: We identified hypoxia-related differentially expressed genes (DEGs) between OC tissues from The Cancer Genome Atlas (TCGA) and normal tissues from the Genotype Read More

Background: Doxorubicin is a significant drug for the treatment of breast cancer, but its cardiotoxicity is an obvious obstacle. Previously, we confirmed that ruthenium complex (Δ-Ru1) and doxorubicin (Δ-Ru1/Dox) combination had a synergistic effect in MCF-7 cells, but its biological effect in vivo is unknown. Purposes: To find a way to overcome the toxicity of doxorubicin and build MCF-7 xenograft tumor mouse model to te Read More

Background: Hepatocellular carcinoma (HCC) is one of the most common cancers, associated with a high rate of mortality. A disturbance between cell proliferation and cell death is one of the cancer hallmarks including HCC. Cell proliferation is mainly controlled by the cell cycle. The arrest of the cell cycle is one of the important targets of anticancer agents. Objectives: The present study tries to clarify the exact role of some n Read More

Background: Tumor metastasis is a main cause of death in patients with breast cancer. The cross-talk between cancer-associated fibroblasts (CAFs) and tumor cells plays an important role in promoting tumor invasion and metastasis. It is important to develop a novel delivery system to inhibit tumor development by simultaneously targeting both CAFs and tumor cells. Objectives: The main objective of this research was to prepa Read More

Background: Lymphoid Enhancer-Binding Factor-1 (LEF1) was previously reported to contribute to a variety of malignancies, including Hepatocellular Carcinoma (HCC). However, its role in HCC is poorly understood. Objectives: To explore the role of LEF1 in HCC, including its prognostic and drug-targeting value. Methods: The LEF1 expression and patient characteristics were investigated. The associations betw Read More

Background: SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells. SV-BR-1-GM and next-generation versions are covered by several pending and granted patents. Methods: We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovaria Read More